3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
25
Ovarian Neoplasms
19
Neoplasms
12
Fallopian Tube Neoplasms
12
Carcinoma, Hepatocellular
11
Endometrial Neoplasms
7
Neoplasm Metastasis
6
Colonic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Glioblastoma
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Lung Neoplasms
3
Liver Neoplasms
3
Digestive System Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mouth Neoplasms
2
Lymphoid Interstitial Pneumonia
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Brenner Tumor
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Astrocytoma
2
Interventions
pembrolizumab
1
durvalumab
1
atezolizumab
1
Standard of Care
1
Immunotherapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Bevacizumab
×
30 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled